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Abstract: CNF1 is a protein toxin produced by certain pathogenic strains of Escherichia 
coli. It permanently activates the regulatory Rho, Rac, and Cdc42 GTPases in eukaryotic 
cells, by deamidation of a glutamine residue. This modification promotes new activities in 
cells, such as gene transcription, cell proliferation and survival. Since the Rho GTPases 
play a pivotal role also in several processes in vivo, the potentiality of CNF1 to act as a 
new pharmacological tool has been explored in experimental animals and in diverse 
pathological contexts. In this review, we give an update overview on the potential in vivo 
applications of CNF1.  
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1. Introduction 
Bacterial protein toxins, the principal virulence factors of pathogenic bacteria, represent one of the 
main bacterial strategies to interact with mammalian cells. Toxins are extremely fascinating molecules. 
By diverse and sophisticated mechanisms, they manipulate the host cell functions in a way that can 
favor the survival and spreading of the microbes. On the other hand, although detrimental to the 
susceptible host during an infection, the activities of several bacterial toxins can be exploited for 
medical applications. It is, in fact, of paramount importance to study how a bacterial toxin acts at 
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molecular level, not only to contrast bacterial diseases, thus subverting its harmful effect but also to 
utilize the toxin as an instrument to control certain cellular pathways 1. 
Toxins are the product of a long-term evolution, and can attack crucial events in the vital processes 
of living organisms, such as components of the protein synthesis machinery, actin polymerization, 
signal transduction pathways, intracellular trafficking of vesicles as well as immune and/or 
inflammatory responses. For this reason, in the last years, some of them, besides representing valuable 
tools for analysis of cellular physiology, have also been successfully employed for treatment or 
prevention of human diseases. The most renowned example is botulinum toxin that, despite its deadly 
toxic effect, it is now widely used in therapy in very small doses to treat different muscle disorders, 
such as muscle spasms, or in various settings for cosmetic procedures 2. 
Here we deal with the Cytotoxic Necrotizing Factor 1 (CNF1) from Escherichia coli that exerts a 
specific enzymatic activity on pivotal molecular switches in eukaryotic cells. In recent years, due to its 
specificity of action on the Rho GTPases (see below), CNF1 has been proved, in experimental animals, 
to possess vaccine adjuvanticity properties, to be effective in enhancing learning and memory, and to 
induce analgesia.  
2. The Cytotoxic Necrotizing Factor 1: In Vitro Effects 
CNF1 is a bacterial protein toxin produced by certain pathogenic strains of E. coli 3 occasionally 
detected in isolates from feces of children with diarrhea 4–6 but, more frequently, responsible of 
extra-intestinal infections, particularly in the urinary tract (UTIs) 3,7,8. Also, these strains can be 
detected in cases of bacteriaemia 9 and of meningitis in neonates 10.  
CNF1 belongs to the so-called dermonecrotic toxins family, including CNF1, CNF2 from E. coli, 
CNFY from Yersinia pseudotubercolosis, and the dermonecrotic toxin DNT from Bordetella, all 
sharing considerable functional and amino acid homologies 11. 
2.1. CNF1 structure and endocytosis  
CNF1, first described in 1983 by Caprioli and coworkers as a toxin capable of causing 
multinucleation ("cytotoxic") in cultured cells and necrosis in rabbit skin ("necrotizing") 12,13, is a 
1,014 amino acid single-chain multidomain protein, containing a N-terminal receptor-binding domain 
and a C-terminal catalytic domain, which modifies a specific cellular target in the host cell cytosol 
14,15. The two domains are separated by an amino-acidic region consisting of two short membrane 
spanning helices H1 (350–372) and H2 (387–412), which are involved in membrane   
translocation 16. 
CNF1 binds to the surface of cultured epithelial cells with high affinity 17. The domain that 
mediates the interaction with the cell surface (amino acids 53 to 190) is able to inhibit the holotoxin 
activity when given to cells in excess 18. Using this receptor binding domain as a bait in the yeast 
two hybrid system, the ubiquitously expressed 37 kDa precursor of the 67 kDa laminin receptor (LRP) 
could be identified as an interaction partner for CNF1 19. Indeed, RhoA activation and bacterial 
uptake (which are the consequences of CNF1 enzymatic activity in cells, see below) are inhibited by 
exogenous LRP or LRP antisense oligodeoxynucleotides 19. Moreover, recently, Kim and 
collaborators have demonstrated that an E. coli K1 strain that expresses CNF1 can be internalized by Toxins 2010, 2 
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HBMECs after the toxin binds to the mature laminin receptor 20. Both the precursor and mature 
forms of the laminin receptor are expressed on the surface of eukaryotic cells and are therefore 
accessible to CNF1 released from bacteria; however, it is unclear whether CNF1 binds preferentially to 
one of the two receptor forms. 
However, competition studies with CNF1 and CNFY suggest that CNF1 has a co-receptor in 
addition to the laminin receptor. Inhibition of heparansulfate proteoglycan (HSPG) expression causes 
delayed cell entry of CNF1 and no uptake of CNFY 21. Thus, HSPGs may represent the receptor for 
CNFY and the co-receptor for CNF1, respectively. Furthermore, a recent study also suggests a co-
receptor for CNF1 due to a second receptor binding part within the CNF1 sequence including the 
amino acids 683 to 730 22. 
After binding to its receptor, CNF1 enters endocytic vesicles by receptor-mediated endocytosis, 
which is independent of clathrin and of sphingolipid-cholesterol-rich membrane microdomains (lipid 
rafts), including caveolae 17. Once inside vesicles, the toxin is routed to the endosomal compartment 
17, where its catalytic domain is transferred into the cytosol. It was postulated that the hydrophilic 
loop, which separates H1 and H2 helices present in the middle part of the CNF1 molecule, is essential 
for translocation of the toxin into the host cell cytosol 16. 
Very recently, it has been demonstrated that an approximately 55-kDa fragment of CNF1, which 
contains the catalytic domain and an additional part of the toxin, is present in the cytosol 23. The 
processing of this fragment requires an acidic pH and insertion of the toxin into the endosomal 
membrane. This is in line with the fact that the pH-dependent membrane translocation step of CNF1 
could be mimicked at the level of the plasma membrane by a brief exposure to a pH of ≤5.2 17. The 
cleavage site of CNF1 is located between amino acids 536 and 542. Experiments with CNF1 mutants, 
which are deficient in the cleavage site, clearly show that the processing and release of the catalytic 
part from the endosomes is essential for the full biologic activity. It is likely that this release occurs 
from late endosomes, because the destruction of the microtubules, which are essential for the 
maturation from early to late endosomes, results in weaker CNF1 toxicity 17,21. 
2.2. CNF1 enzymatic activity 
The C-terminal part of CNF1 (amino acids 720 to 1014) harbors the full catalytic activity 24,25. 
Cysteine 866 and histidine 881 have been found to be crucial for the catalytic activity of CNF1 25. 
The crystal structure identified the third residue of the catalytic triad, valine 833 14. 
The cytoplasmic target of CNF1 is represented by Rho GTP-binding proteins, important molecular 
switches belonging to the Ras superfamily that oscillate between an inactive GDP-bound form 26 
and an active GTP-bound form, which activates effector proteins 27. Transitions between the two 
forms are primarily under the control of regulatory proteins (Figure 1) 28,29. Rho proteins possess a 
low intrinsic GTPase activity and a strong GTPase activity stimulated by the regulatory protein GAP. 
The conformational changes, induced by the binding of GTP or GDP, occur inside two molecular 
domains of the Rho proteins called switches that are responsible of the coupling of the G-proteins with 
their downstream effectors (switch 1) or allow the interaction of the activated GTPase with the 
regulatory proteins GAPs (switch 2).  
The enzymatic activity of CNF1 consists in the deamidation of a specific glutamine residue located 
in the switch 2 domain of the G proteins (glutamine 63 of Rho 30,31 or glutamine 61 of Rac and Toxins 2010, 2 
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Cdc42 32, which is pivotal for the GTPase activity of Rho proteins, either intrinsic or stimulated by 
GAP  33. CNF1 modifies glutamine into glutamic acid, thus impairing the role of GAP and 
permanently blocking Rho proteins in their activated GTP-bound state. This causes constitutive 
activity of these proteins on their effectors (Figure 1). 
Figure 1. Rho GTPases activation/deactivation cycle. Rho GTPases are molecular 
switches that cycle between an inactive GDP-bound form and an active GTP-bound one. 
Activation of Rho GTPases occurs by stimulation with a guanine exchange factor (GEF) 
that causes the release of GDP and the binding of GTP. In the GTP-bound form, Rho 
proteins interact with effector molecules initiating a downstream response. To exert their 
activity Rho proteins require to be attached to membranes. As soon as the activated 
GTPase has initiated the cellular response, a GTPase activating protein (GAP), by 
hydrolyzing GTP into GDP turns back these proteins to their GDP-bound state, to complete 
the cycle and terminate the signal transduction. The conformational changes, induced by 
the binding of GTP or GDP, occur inside two molecular domains of the Rho proteins called 
switches that are responsible of the coupling of the G-proteins with their effectors   
(switch 1) or allow the interaction of the activated GTPase with GAPs (switch 2). Besides 
GEF and GAP proteins, a third factor that regulates Rho GTPases activity is the guanine 
dissociation inhibitor (GDI), which maintains Rho in the cytoplasm in the inactive form 
(linked to GDP). The enzymatic activity of CNF1 consists in the deamidation of a specific 
glutamine residue, located in the switch 2 domain, into glutamic acid thus impairing the 
role of GAP and permanently blocking Rho proteins in their activated GTP-bound state. 
 
The threshold of activation of Rho proteins by CNF1 is, however, attenuated because of a 
concomitant decrease of their cellular levels, due to the depletion of activated-Rho GTPases by 
ubiquitin-mediated proteasomal degradation 34.  
It is worth noting that the activity of CNF1, with its ability to switch on the Rho GTPases and then 
coerce their degradation in the proteasome, shows similarities to the transient activation of Rac and 
Cdc42 proteins by pathogenic Salmonella bearing the virulence factors SopE and SptP, two Rac/Cdc42 
GEF (activation) and GAP (inhibition) functional analogs, respectively 35. This bacterium first 
activates the Rho GTPases, by the GEF-like toxin SopE, to promote engulfment of bacteria into cells Toxins 2010, 2 
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and soon after, once inside, deactivates the GTPases via a GAP-mimicking protein (SptP), thus 
allowing a moderate threshold of Rho protein activation for a high invasion efficiency 36. 
2.3. Effects of CNF1 on eukaryotic cultured cells 
Rho GTPases regulate the organization and dynamic of the actin cytoskeleton through their 
interplay with specific effector proteins 27,37. 
Indeed, by activating Rho proteins, CNF1 provokes a remarkable reorganization of the actin 
cytoskeleton in human epithelial cells that consists in the assembly of F-actin in prominent stress 
fibers, membrane ruffles and filopodia 38,39. Besides extreme flattening of the cell body, CNF1-
treated cultured cells acquire a multinucleated phenotype. This seems to arise from inhibited 
cytokinesis with ongoing nuclear division 23. 
The extensive modifications of the microfilament system induced by the toxin provokes a potent 
and aspecific phagocytic behavior, epithelial cells acquiring the ability to capture and internalize 
different types of particles, such latex beads, apoptotic cells and also bacteria 40,41, through an 
endocytic mechanism known as macropinocytosis. As above described, CNF1-activated Rho GTPases 
undergo sensitization to ubiquitylation and subsequent proteosomal degradation 34, a process that 
would turn off the ruffling process, thus allowing an efficient internalization of bacteria inside the 
cells. Since degradation of Rac increases cell motility and leads to enhanced internalization of bacteria, 
it was speculated that sequential Rho GTPase activation and inactivation limits the inflammatory 
response and promotes survival of bacteria 34. 
Although Rho, Rac and Cdc42 mainly regulate the actin cytoskeleton organization 42, it is known 
that these proteins are also involved in many other cellular processes. Thus, the consequence of CNF1-
induced Rho activation is the induction of a number of actin-dependent or -independent phenomena, 
such the induction of macropinocytosis (see above), contractility, cell spreading 38, assembly of 
focal adhesion plaques 43, transcription 44, cell cycle progression 45, as well as the ability to 
manipulate cell differentiation 46.  
As concerns DNA transcription, we reported that CNF1 can activate the nuclear factor-B (NF-B) 
44 in epithelial cells. Such an activation is responsible for the ability of the toxin to stimulate the 
expression of pro-inflammatory factors 47 and to protect host cell from apoptotic stimuli 48–50. 
Hence, CNF1 is not cytotoxic, as suggested by its name, but rather can be considered as a pro-survival 
factor. Indeed, we have shown that CNF1 hinders UVB-induced apoptotic cell death in HEp-2 
epithelial cells. In particular, the toxin protects cells from the experimentally-induced rounding up and 
detachment and improves cell spreading and the ability of cells to adhere to each other and to the 
extracellular matrix by modulating the expression of proteins related to cell adhesion (integrins, focal 
adhesion kinase, cadherins, catenins) 48. Moreover, CNF1 protects epithelial cells against the drop of 
the mitochondrial membrane potential provoked by UVB radiation and increases the expression of the 
anti-apoptotic members of the Bcl-2 family, Bcl-2 and Bcl-XL 49. In particular, CNF1 up-regulates 
the anti-apoptotic protein Bcl-2 through the activation of the Rac1/PI3K/Akt/IKK/NF-B pro-survival 
pathway. This, in turn, leads to a remarkable modification in the architecture of the mitochondrial 
network, mainly consisting in the appearance of elongated and interconnected mitochondria, which 
contributes to the pro-survival activity of the toxin 50. Toxins 2010, 2 
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As above mentioned, CNF1-induced NF-B activation ensues the transcription and release of pro-
inflammatory cytokines, such as IL-6, IL-8 and TNF- in uroepithelial 47 and endothelial 51 cells 
and up-regulates the transcription of cyclooxygenase- 2 (COX-2) 52. Moreover, after cell activation 
by CNF1, epithelial cells show an increase in oxygen consumption and generate superoxide   
anions 53. 
3. The Cytotoxic Necrotizing Factor 1: In Vivo Effects 
Understanding how CNF1 acts at the molecular level is of importance for using the toxin as an 
instrument to control certain cellular pathways, thus converting a detrimental toxin effect into a 
favorable one. Rho family GTPases are involved in various events being powerful cellular regulators 
and thus rendering CNF1 an attractive putative “drug” in different therapeutic purposes. 
3.1. Learning and memory 
Memory formation is thought to involve the rearrangement of synaptic connections in neuronal 
networks and this is governed by the neuronal actin cytoskeleton 54,55. Actin polymerization is 
chiefly regulated by small GTPases, and in this context, we have recently reported that constitutive 
activation of Rho family GTPases, induced by a single intracerebroventricular injection of CNF1 in 
C57BL/6 and CD1 mice, resulted in rearrangements of actin in cortical neural cells and induced 
sustained enhancement of cognitive performances 56. In particular, CNF1 caused a general 
improvement in associative and spatial learning, as demonstrated in various behavioral tasks. These 
CNF1-induced effects were persistent for months and were absent in animals injected with CNF1 
C866S, the inactive toxin that lacks the enzymatic activity following the substitution of serine to 
cysteine at position 866. 
Learning and memory depend on the morphology and dynamics of dendritic spines and their 
development and structural plasticity is controlled by Rho GTPases and actin cytoskeleton. In line with 
this, CNF1 by activating Rho proteins, induced an enrichment in actin staining both in cerebral 
sections of injected mice and in primary neuronal cells derived from the mouse cortex (Figure 2). 
In this context, we demonstrated that the activation of Rho proteins by CNF1 provokes an increase 
in dendritic surface particularly by spine-like neo-formations, accompanied by actin cytoskeleton 
enrichment. The above changes were not observed when cells were treated with the mutant CNF1 
C866S 56. 
Overall, the results suggest that learning ability can be improved through pharmacological 
manipulation of neural connectivity. These findings raise the possibility that pharmacological agents 
could be used to enhance the changes in neuronal connectivity associated with memory formation, and 
the cytoskeletal components are identified as possible targets for such agents. CNF1 can thus be 
regarded as endowed with long-lasting cognition enhancing properties.  
Furthermore, as well as improving cognition in healthy patients, these drugs could, in theory, be 
used to alleviate the cognitive impairments exhibited by patients with conditions such as   
Alzheimer’s Disease. 
 Toxins 2010, 2 
 
 
289
Figure 2. Effects of CNF1 on actin. Fluorescence microscopy analysis of primary 
neuronal cells derived from the mouse cortex (left panels) and cerebral sections of injected 
mice (right panels). Sections and cells were stained with FITC-phalloidin to detect actin 
cytoskeleton and with Hoechst 33258 to visualize nuclei. The pictures show that CNF1 is 
able to induce an enrichment in actin staining both in vivo and in cell cultures whereas the 
mutant toxin devoid of catalytic activity lacks the ability to modify the actin cytoskeleton. 
 
3.2. CNF1 as adjuvant or drug delivery agent 
Several bacterial toxins, as for example the cholera toxin, have already been described to be 
effective adjuvant 57,58. Adjuvants are vaccine additives that enhance the elicited levels of 
antibodies and T lymphocyte responses 59 in ways that presumably mimic natural infection.  
Initial studies have demonstrated that CNF1 induces production and secretion of pro-inflammatory 
and immunomodulatory cytokines via the activation of Rho proteins 47,60. The subsequent 
investigation of the immunomodulatory effects of CNF1 using a mouse model of oral administration, 
showed that, similarly to cholera toxin, CNF1 elicited adjuvanticity in anti-OVA responses, both 
systemic and mucosal 60. In fact, animals orally immunized with OVA, a prototype soluble antigen, 
and co-administered with CNF1 displayed serum IgG anti-OVA responses. The immunoadjuvant 
properties of CNF1 are related to its enzymatic activity on Rho proteins. In fact, the catalytic inactive Toxins 2010, 2 
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CNF1 C866S failed to enhance serum anti-OVA responses and the catalytic domain of the closely 
related Bordetella dermonecrotic toxin (DNT), a Rho activating toxin, also showed immunoadjuvant 
properties. Thus, the host response to CNF1, in addition to promoting innate immune effectors and 
regulators, may also stimulate the adaptative immune system.  
In the same field, some years later, CNF1 was reported to act as a mucosal adjuvant in 
immunization against tetanus toxoid through nasal route 61. CNF1 plus tetanus toxoid induced a 
specific production of anti-Tetanus toxin (TeNT) IgG that was able to exert a protective effect when 
mice were challenged with TeNT. Conversely, mice immunized with the tetanus toxoid plus  the 
mutant CNF1 C866S died when challenged with TeNT, consistently with the lack of anti-TeNT IgG 
response. An analysis of the TeNT-specific IgG subclasses revealed that the serum antigen response 
was predominantly of IgG1 type, followed by IgG2a whereas seric IgA were found but at a lesser 
extent. This response remained unchanged two and six months later indicating a long lasting specific 
anti-TeNT response induced by CNF1. 
Manipulation of Rho proteins thus provides a possible new approach for the development of 
effective mucosal immunoadjuvants. 
3.3. Analgesic activity of CNF1 
Inflammatory pain is controlled by a complex framework of molecular events, either at the cell 
surface or intracellularly, which have only partially been elucidated. In particular, it seems that the 
actin cytoskeleton influences pain-related signaling 62–64.  
The formalin pain model is a well-established and used model to assess animals’ behavioral 
responses to persistent pain and to examine analgesic effects of drugs. Formalin induced pain derives 
from prolonged tissue damage and represents a model for pain states encountered clinically, such as 
post-operative pain 65. In this context, we have recently reported that peripheral or central 
administration of CNF1 potently counteracted formalin-induced inflammatory pain in mice 66. The 
two phases characterizing the formalin-induced pain, were affected by CNF1 in a different way, 
depending on the route of administration. In fact, i.c.v. injection of the toxin was able to affect both 
phases indicating a central modulating action of CNF1 on neuronal processes associated with both the 
acute phase and the inflammatory tonic phase of the formalin-induced pain. On the other hand, 
peripherally injected CNF1 influenced only the second phase.  
The effects of CNF1 on inflammatory pain were associated with sustained Rac activation and the 
consequent actin cytoskeleton rearrangement. The toxin involves the activation of the Akt/IKK/NF-B 
pathway, as reported in cultured cells, and increases the expression of -opioid receptors (MORs) in 
particular in the PAG area, the part of the pain-modulating circuits characterized by a high density of 
MORs 67. Thus, CNF1, starting from Rac activation, could switch on a series of intracellular events 
including MORs upregulation which probably leads to the observed analgesic effects. This is in line 
with the fact that CNF1 was unable to reduce pain perception in knockout mice for MORs (-/-) 
despite the occurrence of cerebral Rac activation. The hypothesis is that CNF1-induced MORs 
upregulation could provide additional links to the endogenous opioids released after formalin 
stimulation, thus reducing the pain threshold. This finding discloses new possibilities for the 
pharmacological control of inflammatory pain.  
 Toxins 2010, 2 
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4. Conclusions 
Bacterial toxins play an important role in infectious diseases, and several of them are amongst the 
most potent biological agents known to man. Cholera, pertussis, botulinum, clostridium and tetanus 
toxins are all produced by bacteria and, in many cases, it is the toxin produced and not the infectious 
agent itself that causes pathology. Also, botulinum, anthrax, and other toxins, have potentially 
devastating effects if misused as an agent of biological terror. However, although detrimental to the 
susceptible host during an infection, the activities of several bacterial toxins can be exploited for 
medical applications 1. 
In this review, we have focused our interest on CNF1, on its applications and therapeutical 
potential, describing the state of art of its possible employment in therapy. Although the first report on 
this aspect concerns the adjuvancy of CNF1 and its ability to engage the immune system, in our view, 
the most fascinating aspect of this toxin resides in its potentiality to act on the “synaptic plasticity” in 
the nervous system. Synaptic plasticity is acknowledged to depend on actin dynamics that are 
controlled by Rho GTPases. Importantly, Rho GTPase signaling and spine morphology are 
consistently affected in human memory disorders, including Alzheimer’s Disease (AD). Therefore, 
CNF1 acts on a mechanism that might represent a rate-limiting step for cognition in humans. Memory 
disorders are characterized also by alterations in NF-B signaling, which lies downstream Rho 
GTPases and has been implicated in adult neurogenesis modulation. With this in mind, it stems the 
uniqueness of CNF1 that controls actin dynamics via Rho signaling as well as NF-B activation in any 
kind of tissue investigated so far, including the brain. Hence, a pharmacological intervention at the 
level of the Rho GTPases themselves or their downstream effectors (NF-B) may be the most effective 
strategy to manipulate synaptic plasticity underlying memory. These considerations imply the potential 
pharmacological importance of the molecule which could, in theory, be used to alleviate the 
impairments exhibited by patients with cognitive disorders. 
On the other hand, Rho proteins, particularly Rac, are also involved in inflammatory pain 
perception. The ability to activate the Rac GTPase at both cerebral and peripheric sites, renders CNF1 
a useful tool for the comprehension of the fine mechanisms underlying pain. More importantly, these 
findings can disclose a new scenario for the pharmacological control of inflammatory pain, that is the 
possibility to overcome the “classical” receptor ligation-mediated pain control by introducing a new, 
intracellularly regulated path aimed at the modulation of pain perception.  
Although it has been shown that the i.c.v injection of the entire CNF1 toxin causes no lethal effects 
in animals 56,66, it still remains difficult to propose the use of such a high molecular weight protein 
(114 kDa) for therapeutic purposes. This problem could be overcome by constructing recombinant 
molecules composed by CNF1-derived peptides that maintain the catalytic Rho GTPase activating 
capacity and that will be vehiculated in the CNS with delivery systems such as nanoparticles.  
In conclusion, the presumed therapeutic properties of CNF1 arises a question: can we consider this 
toxin as a “magic bullet” for the nervous system? 
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